Quest Diagnostics announced a new collaboration with City of Hope, one of the nation’s largest cancer research and treatment organizations, to deploy the company’s Haystack MRD circulating‑tumor‑DNA test in clinical trials for breast, colorectal, ovarian, and prostate cancer patients. The multi‑year program will span fourteen City of Hope sites across the United States and is expected to enroll roughly 500 patients, generating thousands of longitudinal measurements of minimal residual disease.
The partnership underscores Quest’s strategy to broaden its advanced diagnostics offerings and to capture a high‑margin revenue stream from liquid‑biopsy technology. Haystack MRD, a tumor‑informed next‑generation MRD test that detects circulating tumor DNA, received FDA Breakthrough Device designation for stage II colorectal cancer in 2025, positioning it as a leading solution in the rapidly growing liquid‑biopsy market.
Quest Diagnostics’ recent financial performance provides context for the partnership’s potential impact. The company reported Q4 2025 revenues of $2.81 billion, up 7.1% from 2024, and full‑year 2025 revenues of $11.04 billion, up 11.8% from 2024. For 2026, Quest guided full‑year revenues of $11.70 billion to $11.82 billion and adjusted diluted EPS of $10.50 to $10.70, reflecting confidence in continued growth and margin expansion as new high‑margin tests are adopted.
Dan Edelstein, Vice President and General Manager of Haystack Oncology, said, “City of Hope is one of the nation’s foremost cancer centers, with a century‑long commitment to advancing cancer care through both research and clinical excellence, and we have built a strong relationship with them over time. Haystack MRD is designed to help clinicians and their patients act earlier with greater confidence, based on the principle that cancer survivors and their care teams should be able to make proactive, not reactive, healthcare decisions. We believe the research collaboration will generate important evidence supporting the role of Haystack MRD in informing patient management across multiple solid tumor settings.”
Cristian Tomasetti, Ph.D., Professor and Director of the Center for Cancer Prevention, Early Detection and Monitoring at City of Hope, added, “City of Hope brings together the scientific expertise, clinical infrastructure, and advanced technology needed to evaluate emerging approaches that can meaningfully improve cancer care and health outcomes for patients. We see liquid biopsy as an important frontier in oncology and aim to leverage the most accurate and effective commercially available ctDNA assays while also working to develop effective early detection platforms. We are excited to study how Haystack MRD might inform treatment decisions across several solid tumor types.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.